论文信息 - Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society

According to the recent American Academy of Neurology (AAN) guideline update, a drug can be recommended as possibly effective for migraine prevention if it had demonstrated efficacy in one Class II study.1 Eight drugs are recommended as possibly effective,1 and there are several drugs for which I would question the evidence. Due to space limitations, I have chosen just one example.

P. Tfelt-Hansen | N. Sethi

[1] Karl J. Friston,et al. A Bayesian account of ‘hysteria’ , 2012, Brain : a journal of neurology.

[2] S. Silberstein,et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults , 2012, Neurology.

[3] R. Duncan,et al. Early outcomes and predictors in 260 patients with psychogenic nonepileptic attacks , 2010, Neurology.

[4] H. Diener,et al. The First Placebo-Controlled Trial of a Special Butterbur Root Extract for the Prevention of Migraine: Reanalysis of Efficacy Criteria , 2004, European Neurology.

[5] S. Silberstein. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review) , 2000, Neurology.

[6] J. Lance,et al. A COMPARATIVE TRIAL OF PRINDOLOL, CLONIDINE AND CARBAMAZEPINE IN THE INTERVAL THERAPY OF MIGRAINE , 1972, The Medical journal of Australia.

[7] M. Edwards,et al. Trick or treat? Showing patients with functional (psychogenic) motor symptoms their physical signs. , 2012, Neurology.